ICSI后使用SrCl2或卡西霉素进行人工卵母细胞激活与单独ICSI相比改善临床和胚胎学结局:一项随机临床试验结果
这项随机、开放标签、三臂、平行组、双中心、优效性试验于2015年4月至2016年1月纳入343对夫妇,比较ICSI后SrCl2或卡西霉素人工卵母细胞激活与单独ICSI的临床妊娠率。结果显示两种激活剂均提高临床妊娠、持续妊娠和活产率,且对不同亚组效应不同。
要点
- SrCl2和卡西霉素激活组临床妊娠率分别为49%和42%,均高于单独ICSI组的27%。
- 既往ICSI低受精夫妇中,仅SrCl2激活在临床妊娠、持续妊娠和活产率上优于单独ICSI。
- 男性因素不育夫妇中,仅卡西霉素激活在临床妊娠、持续妊娠和活产率上优于单独ICSI。
核心结论
- ICSI后使用SrCl2或卡西霉素进行人工卵母细胞激活与单独ICSI相比可提高临床妊娠、持续妊娠和活产率,且两种药物对不同患者亚组效应不同。
- 作者认为,选择SrCl2还是卡西霉素进行人工卵母细胞激活可能取决于激活失败源于卵母细胞还是精子。
研究设计与样本
- 随机、开放标签、三臂、平行组、双中心、优效性试验,于2015年4月至2016年1月开展,纳入343对夫妇分为三组。
- 纳入标准为既往两次ICSI周期无或低受精(0-30%)且原因不明或卵母细胞形态受损,或首次ICSI且男方因素不育(冻融精子、手术获取精子或精液精子浓度<10百万/ml)并100%异常精子形态(包括圆头精子和锥头精子)。
- 夫妇随机接受ICSI后SrCl2激活、ICSI后卡西霉素激活或单独ICSI,主要终点为临床妊娠。
- 效应量以绝对率差(ARD)和比值比(OR)表示,精确度用95%CI评估。
主要发现
- SrCl2组、卡西霉素组和单独ICSI组临床妊娠率分别为49%、42%和27%;SrCl2 vs 单独ICSI的ARD为22(95%CI:9-33,P=0.0007),卡西霉素 vs 单独ICSI的ARD为16(95%CI:3-27,P=0.014)。
- SrCl2组、卡西霉素组和单独ICSI组持续妊娠率分别为42%、36%和23%(SrCl2 vs 单独ICSI P=0.0019;卡西霉素 vs 单独ICSI P=0.023)。
- SrCl2组、卡西霉素组和单独ICSI组活产率分别为40%、33%和18%(SrCl2 vs 单独ICSI P=0.0002;卡西霉素 vs 单独ICSI P=0.012)。
- 既往ICSI低受精夫妇中,SrCl2激活 vs 单独ICSI的临床妊娠ARD为35个百分点(P=0.0007),持续妊娠ARD为27个百分点(P=0.009),活产ARD为37个百分点(P=0.002);卡西霉素激活未显示优于单独ICSI。
- 男方因素不育夫妇中,卡西霉素激活 vs 单独ICSI的临床妊娠ARD为22个百分点(P=0.006),持续妊娠ARD为19个百分点(P=0.013),活产ARD为17个百分点(P=0.02);SrCl2激活未显示优于单独ICSI。
临床怎么用
- 作者认为,ICSI后选择SrCl2或卡西霉素进行人工卵母细胞激活可能取决于激活失败源于卵母细胞还是精子。
局限性
- 本研究为开放标签试验,尽管采用了随机化方法,该设计可能引入偏倚。
- 本研究未包括纵向随访,因此需要进一步证据来证明人工卵母细胞激活的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are pregnancy and birth rates affected by artificial oocyte activation (AOA) with SrCl2 or calcimycin after ICSI for couples with male-factor infertility linked to abnormal sperm morphology or for couples with previous ICSI cycles of unexplained low fertilization or inadequate fertilization associated with impaired oocyte morphology? SUMMARY ANSWER: AOA with either SrCl2 or calcimycin can improve the rates of clinical pregnancy, ongoing pregnancy and live birth compared with ICSI alone, and the two agents have diverse effects for different subgroups of patients. WHAT IS KNOWN ALREADY: ICSI is a successful treatment for infertility, but not in all individuals. AOA has potential to overcome inadequate fertilization in ICSI. Calcimycin and SrCl2 are candidate agents for AOA, but their effectiveness remains to be compared. STUDY DESIGN, SIZE, DURATION: This study was a randomized, open-label, three-arm, parallel-group, double-centre, superiority trial conducted between April 2015 and January 2016. The study evaluated the effects of AOA with calcimycin or SrCl2 for clinical pregnancy rates after ICSI and included 343 couples divided into three groups. PARTICIPANTS/MATERIALS, SETTING, METHODS: Couples were included if they had two previous ICSI cycles of no or low fertilization (0-30%) with unknown causes or impaired oocyte morphology. Male-factor infertility cycles (frozen-thawed sperm, surgically retrieved sperm or ejaculates contained <10 millions spermatozoa/ml) undergoing their first ICSI attempt were also included if they had 100% abnormal sperm morphology (including globozoospermia and tapered-head). Couples were randomized to undergo ICSI with SrCl2 AOA, ICSI with calcimycin AOA or ICSI alone, with clinical pregnancy as the primary endpoint. Effect sizes were summarized as absolute rate differences (ARDs) and odds ratios (ORs), with precision evaluated by 95% CIs. MAIN RESULTS AND THE ROLE OF CHANCE: Both SrCl2 and calcimycin AOA improved clinical pregnancy rates compared to ICSI alone (49, 42 and 27%; ARD 22, 95% CI: 9-33; P = 0.0007 and ARD 16, 95% CI: 3-27; P = 0.014). SrCl2 and calcimycin AOA were also superior to ICSI alone on the rates of ongoing pregnancy (42, 36 and 23%; P = 0.0019 and P = 0.023) and live birth (40, 33 and 18%; P = 0.0002 and P = 0.012). Among couples with previous ICSI cycles of low fertilization, AOA with SrCl2 (but not with calcimycin) was superior to ICSI alone for rates of clinical pregnancy (ARD 35 percentage points (pp), P = 0.0007), ongoing pregnancy (ARD 27 pp, P = 0.009) and live birth (ARD 37 pp, P = 0.002). Among couples affected by male-factor infertility, AOA with calcimycin (but not with SrCl2) was superior to ICSI alone for rates of clinical pregnancy (ARD 22 pp, P = 0.006), ongoing pregnancy (ARD 19 pp, P = 0.013) and live birth (ARD 17 pp, P = 0.02). LIMITATIONS, REASONS FOR CAUTION: This study was an open-label trial, and this design might have introduced bias, although randomization methods were used. The study did not include a longitudinal follow-up, so further evidence is required to demonstrate the safety of AOA. WIDER IMPLICATIONS OF THE FINDINGS: The decision to use SrCl2 or calcimycin for AOA after ICSI may depend on whether the activation failure originates in the oocyte or the sperm. STUDY FUNDING/COMPETING INTEREST(S): The study received no funding and the authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: NCT02424214. TRIAL REGISTRATION DATE: 22 April 2015. DATE OF FIRST PATIENT’S ENROLMENT: 27 April 2015.
引用
- Fawzy M, Emad M, Mahran A, et al. Artificial oocyte activation with SrCl2 or calcimycin after ICSI improves clinical and embryological outcomes compared with ICSI alone: results of a randomized clinical trial. Hum Reprod. 2018. PMID: 30099496. doi:10.1093/humrep/dey258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。